Arterium’s Post

🇫🇮 Finland: An Ideal Environment for the Pharmaceutical Industry's Real-World Evidence (#RWE) Studies Finland offers an ideal environment for the pharmaceutical industry's Real-World Evidence (RWE) studies. Legislation’s clear guidelines ensure that healthcare data can be combined from various registers. Finnish #hospital #data lakes provide access to nearly all patient information collected in hospital databases. Pharmaceutical companies should consider Finland when evaluating locations for Real-World Evidence (RWE) studies. The country boasts numerous strengths that make it an outstanding choice for real-world data-based (RWD) research.  “Finland’s strong tradition and extensive experience in utilizing healthcare registries for research make it unique,” says Dr. Riikka Mattila, Scientific Advisor at Medaffcon. Legislation Provides Guidelines for the #Pharmaceutical Industry's Real-World Evidence (RWE) Studies  ➡ Do you want to know more? ➡ https://lnkd.in/dsjGq-Ya #RWD #Nordic

The inauguration of the 73rd Indian Pharmaceutical Congress is a significant event that marks the beginning of this prestigious gathering of pharmaceutical professionals and experts. It typically involves ceremonial activities, speeches by key figures in the industry, and the official opening of the congress. The inauguration sets the tone for the rest of the event, highlighting the importance of collaboration, innovation, and knowledge sharing in the pharmaceutical sector. It's a momentous occasion that signifies the coming together of individuals dedicated to advancing healthcare and pharmaceutical sciences in India. #Hetero #indanpharmaceuticalcongress #healthcareinnovation #pharmaindustry

Our experts, Mallikaarjunan R and Jurairat Buasuwan were invited recently to speak on ‘Thailand’s Pharmaceutical Industry and New Drug Research and Development’, as part of the Drug Information Association (DIA) China. The discussion was hosted by handsome ji, DIA China RAC / GRO, Pfizer. Our latest blog references insights from the presentations and Mallikaarjunan’ s recent article on ‘Global Clinical Trials’ published in PharmiWeb.com: Life Science News & Resources. It highlights Thailand’s pharmaceutical landscape, Navitas Life Sciences’ unparalleled contributions, and the global implications of innovative clinical trials. Read Now: https://lnkd.in/g4dgkP6Q #globalclinicaltrials #regulatoryaffairs #complextrials #pharmacovigilance

This is a time of unprecedented change in #marketaccess for new drugs in Europe that will drive major organizational changes in pharmaceutical companies and biotechs, as well as in the evaluating agencies and decision-making bodies for pricing and financing. As of today, how the regulatory changes will be implemented at the operational level remains the biggest #uncertainty. From Alira Health we have collected the #keypoints of these regulations and the #keyissues of concern for the main players in the #ATMPs environment. 💪 We look forward to accompanying many companies and biotechs in this exciting period! https://lnkd.in/d-drRkw8

At the 2023 Fifteenth China Conference of Pharmaceutical Entrepreneurs, Scientists and Investors, held in Hangzhou from Nov. 1 to 3, the 2023 list of Top 100 China Innovative #Pharmaceutical Businesses was officially released with #Tasly Pharma in the Top 25. The “Top 100” was voted in consideration of three aspects, basis for innovation, process of innovation, and achievement from innovation. Besides, the list was resolved by reference to four indicators including clinical trial count, licensed innovative drug count, and marketed product count. The Top 100 innovative companies, as the first line-up showcasing China’s capabilities of pharmaceutical originality, form the mainstay of China’s pharmaceutical sector in transformation, upgrading, and development of competitive edge, and provide the experience and benchmarks on which their successors will be drawing.

Honored to be a part of the International Conference on Emerging Pharmaceutical Trends in Islambad! Excited to learn from industry experts and network with fellow professionals. Looking forward to gaining insights on the latest advancements and innovations in the pharmaceutical industry. #PharmaceuticalConference #EmergingTrends

I had the great opportunity to attend the CAPRA 2024 Pharmaceutical Symposium this week, thanks to the recommendation of my dear friend Michael Lopez and the encouragement of Natasha Radhay who both made me aware of CAPRA and its significance. During the event, I had the pleasure of meeting Karen Reynolds, General Manager of the Pharmaceutical Drugs Directorate (PDD) at Health Canada, and learning more about the evolving regulatory landscape. One of the standout topics was the latest guidance on nitrosamine impurities in medications. This guidance, covers the evaluation and management of risks related to N-nitrosamine impurities in human pharmaceutical, biological, and radiopharmaceutical products. Given the global concern about the potential health risks of nitrosamine impurities, it was enlightening to hear about the latest strategies for mitigating these risks. It was an enriching experience to learn from the panelists and network with other professionals.  #PharmaceuticalRegulation #CAPRA2024 #Nitrosamines #HealthCanada #RegulatoryAffairs

🇮🇪 🇮🇸 Quick Pharm & Heilsa Achieve First-Ever Serialisation in Iceland 🇮🇸 🇮🇪 In collaboration with Heilsa, a leading pharmaceutical parallel importer in Iceland, we've successfully serialised their first pharmaceutical packs specifically for the Icelandic market. This achievement is a significant milestone, not only for Quick Pharm Solutions and Heilsa, but for the entire pharmaceutical industry in Iceland. It comes at a crucial time, as medicine shortages continue to impact Iceland and Europe. Serialisation plays a vital role in ensuring the authenticity and traceability of medicines, ultimately protecting patients from counterfeit drugs. Together with Heilsa, we're paving the way for a safer and more secure pharmaceutical supply chain in Iceland.👊 #QuickPharmSolutions #Heilsa #Iceland #PharmaceuticalSerialisation #PharmaIndustry #MedicineShortages #PatientSafety #SupplyChain

Hi All Just to share, last one week was spectacular and fully loaded with several interactions in 73rd IPC, and CRSI. It was glad to meet several industry professionals, research professionals, and academicians. PharmaDEM could certainly made it's visibility meeting them, and discussing on the technology transformation contribution it is doing to align with Pharma4.0. PharmaDEM has also delivered tech talk by its CSO, Dr.Ravi Shekhar Ananthula, to technically reach the Pharma fraternity professionals on our thought process, solution deliveries in the larger interest on "how to save time", "how to save cost" and "how to accelerate R&D" Thanks for all who visited us, and for all who been continuously supporting us. Please join the league of technology transformation

Excellent opportunity to discuss the evolving ATMP (advanced therapy medicinal product) ecosystem in Europe at #adtherapies24. A great privilege to learn from my fellow panelists Thomas Bols, Alexander Natz, Elisabetta Zanon, and Thomas Ecker. Questions remain re the final implementation of the EU joint clinical and health technology assessments but optimism prevails that much needed incentives for pharmaceutical innovation will be predominant against the backdrop of the revised European pharmaceutical legislation. #EU #ATMP #CellandGene #HTA #PharmaceuticalPackage #Access Advanced Therapies